CIK 1839435
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 89.86% | 25 |
| Unclassified | 10.14% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 18.08% |
| 2 | COGT | Cogent Biosciences, Inc. | Health Care | 10.01% |
| 3 | ABVX | Abivax S.A. | Health Care | 8.34% |
| 4 | ALMS | ALUMIS INC. | Health Care | 6.90% |
| 5 | DFTX | Definium Therapeutics, Inc. | Health Care | 5.10% |
| 6 | AVBP | ArriVent BioPharma, Inc. | Health Care | 5.03% |
| 7 | TSHA | Taysha Gene Therapies, Inc. | Health Care | 4.38% |
| 8 | KYMR | Kymera Therapeutics, Inc. | Health Care | 3.92% |
| 9 | MIRM | Mirum Pharmaceuticals, Inc. | Health Care | 3.46% |
| 10 | BIOA | BioAge Labs, Inc. | Health Care | 3.38% |
25/29 names classified · sector 89.9% of weight · industry 89.9% · mkt cap 79.6%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 89.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/27 names) · unclassified 100.0%: DNTH, COGT, , ABVX, ALMS, DFTX, AVBP, TSHA, KYMR, MIRM +17 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DNTHDIANTHUS THERAPEUTICS INC | 1,946,667 | $163M | 18.1% | TRIM −19% |
| 2 | COGTCOGENT BIOSCIENCES INC | 2,350,000 | $90M | 10.0% | HOLD |
| 3 | ABVXABIVAX SA | 677,000 | $75M | 8.3% | TRIM −10% |
| 4 | ALMSALUMIS INC | 2,830,700 | $62M | 6.9% | ADD 12% |
| 5 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 2,440,000 | $46M | 5.1% | NEW |
| 6 | AVBPARRIVENT BIOPHARMA INC | 1,971,054 | $45M | 5.0% | HOLD |
| 7 | TSHATAYSHA GENE THERAPIES INC | 8,859,911 | $40M | 4.4% | HOLD |
| 8 | KYMRKYMERA THERAPEUTICS INC | 425,000 | $35M | 3.9% | TRIM −21% |
| 9 | MIRMMIRUM PHARMACEUTICALS INC | 338,900 | $31M | 3.5% | NEW |
| 10 | BIOABIOAGE LABS INC | 1,748,000 | $31M | 3.4% | ADD 9% |
| 11 | CENTESSA PHARMACEUTICALS PLC | 750,000 | $30M | 3.3% | HOLD |
| 12 | KALVISTA PHARMACEUTICALS INC | 1,450,000 | $29M | 3.2% | ADD 14% |
| 13 | XENEXENON PHARMACEUTICALS INC | 490,000 | $28M | 3.2% | NEW |
| 14 | TERNS PHARMACEUTICALS INC | 530,000 | $28M | 3.1% | NEW |
| 15 | OCULOCULAR THERAPEUTIX INC | 3,166,600 | $27M | 3.0% | ADD 21% |
| 16 | PALIPALISADE BIO INC | 10,276,317 | $18M | 2.0% | ADD 7% |
| 17 | TRVITREVI THERAPEUTICS INC | 1,485,000 | $18M | 2.0% | TRIM −47% |
| 18 | IRONDISC MEDICINE INC | 270,000 | $17M | 1.9% | NEW |
| 19 | AKTSAKTIS ONCOLOGY INC | 960,847 | $17M | 1.9% | NEW |
| 20 | CNTXCONTEXT THERAPEUTICS INC | 5,250,000 | $14M | 1.5% | NEW |
| 21 | DTILPRECISION BIOSCIENCES INC | 2,236,732 | $12M | 1.4% | ADD 17% |
| 22 | DBVTDBV TECHNOLOGIES S A | 574,200 | $12M | 1.3% | HOLD |
| 23 | UNCYUNICYCIVE THERAPEUTICS INC | 1,000,000 | $7M | 0.7% | HOLD |
| 24 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 719,000 | $6M | 0.7% | TRIM −31% |
| 25 | LXEOLEXEO THERAPEUTICS INC | 1,100,000 | $6M | 0.7% | TRIM −36% |
| 26 | PHVSPHARVARIS N V | 165,000 | $5M | 0.5% | TRIM −75% |
| 27 | CATXPERSPECTIVE THERAPEUTICS INC | 791,555 | $3M | 0.4% | NEW |
| 28 | EVMNEVOMMUNE INC | 143,472 | $3M | 0.4% | TRIM −71% |
| 29 | GOSSGOSSAMER BIO INC | 7,750,000 | $3M | 0.3% | TRIM −44% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DNTHDIANTHUS THERAPEUTICS INC | 2.1M | 2.3M | 2.3M | 2.4M | 2.4M | 1.9M | $163M |
| COGTCOGENT BIOSCIENCES INC | 2.8M | 2.8M | 2.8M | 2.9M | 2.4M | 2.4M | $90M |
| ABVXABIVAX SA | — | 1.2M | 1.3M | 1.3M | 756K | 677K | $75M |
| ALMSALUMIS INC | — | — | — | — | 2.5M | 2.8M | $62M |
| DFTXDEFINIUM THERAPEUTICS INC COM SHS | — | — | — | — | — | 2.4M | $46M |
| AVBPARRIVENT BIOPHARMA INC | 2.1M | 2.1M | 1.9M | 2.0M | 2.0M | 2.0M | $45M |
| TSHATAYSHA GENE THERAPIES INC | 10.4M | 10.7M | 12.6M | 9.1M | 8.9M | 8.9M | $40M |
| KYMRKYMERA THERAPEUTICS INC | — | — | 266K | 360K | 535K | 425K | $35M |
| MIRMMIRUM PHARMACEUTICALS INC | — | — | — | — | — | 339K | $31M |
| BIOABIOAGE LABS INC | — | — | — | — | 1.6M | 1.7M | $31M |
| CENTESSA PHARMACEUTICALS PLC | 2.0M | 1.4M | 1.0M | 830K | 750K | 750K | $30M |
| KALVISTA PHARMACEUTICALS INC | 1.4M | 1.4M | 1.3M | 1.3M | 1.3M | 1.4M | $29M |
| XENEXENON PHARMACEUTICALS INC | — | — | — | — | — | 490K | $28M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | — | 530K | $28M |
| OCULOCULAR THERAPEUTIX INC | 2.4M | 2.4M | 2.4M | 2.6M | 2.6M | 3.2M | $27M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
